Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

R Samuel Saks


  • Director at Pdl Biopharma Inc. (PDLI), 2019-06-25
  • Chief Medical Officer at Protagonist Therapeutics Inc (PTGX), 2019-05-16
  • Director at Tonix Pharmaceuticals Holding Corp. (TNXP), 2018-06-13
  • Director at Depomed Inc (DEPO), 2016-05-20
  • Chief Development Officer at Auspex Pharmaceuticals Inc. (ASPX), 2015-05-06
  • Director at Trubion Pharmaceuticals Inc (TRBN), 2010-10-28
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
TNXP $2.00 12,500 Director 51,050 2016-06-21 Filing
TNXP $2.00 25,000 Director 63,550 2016-06-21 Filing
TNXP $7.50 10,000 Director 32,550 2015-07-17 Filing
ASPX $12.00 2,175 Officer, Director 63,839 2014-02-10 Filing
TNXP $0.00 5,883 Director 22,550 2013-08-14 Filing